Interviews | Page 12

benefits-and-risks-of-off-label-use-of-noacs
Alexander Kantorovich, PharmD, BCPS, clinical assistant professor of pharmacy practice at Chicago State University College of Pharmacy, discusses the benefits and risks of off-label use of new oral anticoagulants.
how-can-pharmacists-file-a-report-with-medwatch-
Teresa Rubio, PharmD, of the FDA Office on Health and Constituent Affairs, describes the process by which pharmacists can file reports with MedWatch.
what-types-of-ades-should-pharmacists-report-to-medwatch
Teresa Rubio, PharmD of the FDA Office on Health and Constituents Affairs describes the types of adverse drug events that pharmacists should report to MedWatch.
how-pharmacists-can-be-proactive-in-reducing-the-chance-of-errors
Natasha Nicol, PharmD, FASHP, director of Global Patient Safety Affairs at Cardinal Health, talks about how a pharmacist can be proactive in reducing the chance of errors.
prevention-strategies-pharmacists-can-use-to-reduce-errors
Natasha Nicol, PharmD, FASHP, director of Global Patient Safety Affairs at Cardinal Health, provides prevention strategies to reduce medication errors.
concerns-with-medication-use-risk-outside-of-pharmacy
Matthew C. Grissinger, RPh, FISMP, FASCP, director, of error reporting programs at the Institute for Safe Medication Practices, discusses medication use risk outside the pharmacy.
negative-trends-affecting-the-pharmacy-workforce-
James Hoffman, PharmD, MS, FASHP, describes negative trends affecting the pharmacy workforce.
how-renal-function-affects-noac-dosing
Alexander Kantorovich, PharmD, BCPS, clinical assistant professor of pharmacy practice at Chicago State University College of Pharmacy, discusses how a patient’s renal function affects appropriate dosing of new oral anticoagulants.
how-practice-settings-will-be-affected-by-changing-pharmacy-trends
James Hoffman, PharmD, MS, FASHP, explains how pharmacy practice settings may change going forward.
noac-dosing-for-obese-patients-vs-non-obese-patients
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses how NOAC dosing for obese patients differs from NOAC dosing for non-obese patients.
$AD300x250BB$
Latest Issues
$auto_registration$